Article Figures & Data
Figures
- Abstract 227 Figure 1
(A) Representative images and quantification of (B) MBP+ or (C) Nk×2.2+ cells following exposure to PGE2. (D) Expression of PGE2 receptors in OPCs. (E) Images and (F) quantification of MBP+ cells from EP1−/− and control mice exposed to PGE2.
- Abstract 233 Figure 1
- Abstract 325 Figure 1
Scatter plot showing relationship of PDL1 expression (percent of image pixels positive) and CD4 lymphocyte infiltration (as measured by percent image pixels positive) in HNSCC.
- Abstract 359 Figure 1
- Abstract 366 Figure 1
- Abstract 376 Figure 1
Tables
- Abstract 230 Table 1
Study Week Weight (kg) Height (cm) Waist Circ. (cm) BMI-%ile TBF (%) FFM (%) Week 0 81.9±24.6 157.7±7.1 104.1±15.7 94.8±10.0 28.1±7.7 71.8±7.8 Week 24 77.8±24.0 158.7±7.1 103.6±14.7 92.3±12.4 26.0±8.7 74.1±8.7 p-value < 0.001 <0.001 0.64 0.01 <0.001 <0.001 - Abstract 239 Table 1
VMC Sub-population
ααCNTL (n=14)
<3%Heart Failure (n=10)
<3%ββ 61% +/–17% 83% +/–11%** αβ 30% +/–19% 7% +/–5%** - Abstract 241 Table 1
Endpoints ECMO to VAD to OHT (n=10) ECMO to OHT (n=4) Log Rank
P-Value1-Year Actuarial Survival 90.0% 50.0% 0.068 1-Year Actuarial Freedom from CAV 66.7% 25.0% 0.295 1-Year Actuarial from NF-MACE 85.7% 100.0% 0.593 1-Year Actuarial Freedom from Any Treated Rejection 90.0% 100.0% 0.507 P=NS.
- Abstract 242 Table 1
Endpoints Group A
No Anti-HTN Medication
(n=30)Group B
1 Anti-HTN Medication
(n=30)Group C
2 Anti-HTN Medications
(n=56)Group D
≥ 3 Anti-HTN Medications
(n=24)P-Value 3-Year Actuarial Survival 100.00% 89.80% 84.10% 91.70% 0.592 3-Year Actuarial Freedom from CAV 88.20% 95.80% 80.20% 79.30% 0.261 3-Year Actuarial Freedom from NF-MACE 100.00% 96.70% 86.80% 100.00% 0.067 1-Year Actual Freedom from Any Treated Rejection 93.30% 90.00% 77.60% 86.20% 0.398 1-Year Actual Freedom from Antibody Mediated Rejection 96.70% 93.30% 96.40% 100.00% 0.631 1-Year Actual Freedom from Acute Cellular Rejection 93.30% 96.70% 86.80% 91.00% 0.636 1-Year Actual Freedom from Biopsy Negative Rejection 100.00% 100.00% 90.70% 95.20% 0.194 Interventricular Septal Thickness (IVS) > 1.2 cm 10.0% (3/30) 13.3% (4/30) 16.1% (9/56) 16.7% (4/24) P=NS Left Ventricular Posterior Wall (LVPW) > 1.2 cm 3.3% (1/30) 6.7% (2/30) 7.1% (4/56) 8.3% (2/24) P=NS P=NS.
- Abstract 246 Table 1
Study Week LDL Chol(mg/dl) HDL Chol(mg/dl) TG(mg/dl) BMI-%ile FFM(%) A1c(%) Week 0 97±20 36±8 172±89 95±10 71.8±7.8 5.9±0.7 Week 24 79±17 42±9 106±47 92±12 74.1±8.7 5.6±0.5 p-value <0.0001 <0.001 <0.0001 <0.05 <0.001 <0.001 - Abstract 247 Table 1
Statistical Data A1C Glycomark Age Diabetes Duration BMI Mean 24h Glucose Mean Glucose excursion Gender Slope 7.77 –1.49 0.45 0.44 –2.11 0.16 0.15 NA R-Squared 0.02 0.03 0.06 0.03 0.09 0.03 0.03 NA p value 0.44 0.34 0.14 0.32 0.06 0.32 0.33 0.86 - Abstract 254 Table 1
ARE Detection Performance by TCM, mCAP, Respiratory Rate and Pulse-oximetry
Total ARE 132 Mean ARE per minute detected by each modality TCM 0.065/minute Capnography 0.179/minute Respiratory Rate 0.003/minute Pulse-oximetry 0.019/minute - Abstract 263 Table 1
Models for prediction of survival without BPD
Full cohort (n=507) Genetic cohort (n=414) OR(95% CI) P value OR(95% CI) P value OR(95% CI) P value AFR ancestry 2.6(1.4, 4.8) 0.002 AA 2.0(1.3, 3.2) 0.003 2.6(1.5, 4.4) 0.0004 Hispanic 1.2(0.6, 2.5) 0.55 1.7(0.8, 3.6) 0.19 Other 1.8(0.7, 4.5) 0.19 2.4(0.9, 6.6) 0.08 Birth weight 1.0(1.0, 1.0) 0.01 1.0(1.0, 1.0) 0.004 1.0(1.0, 1.0) 0.005 Birth weight centile 1.0(1.0, 1.0) 0.94 1.0(1.0, 1.0) 0.61 1.0(1.0, 1.0) 0.59 Male sex 0.4(0.3, 0.7) 0.0004 0.4(0.3, 0.7) 0.001 0.4(0.2, 0.7) 0.0003 Multiple gestation 1.1(0.7, 1.8) 0.62 1.2(0.7, 2.0) 0.41 1.2(0.7, 2.0) 0.46 RSS (MAPxFiO2) at study entry 0.7(0.6, 0.8) <0.0001 0.7(0.6, 0.8) <0.0001 0.7(0.6, 0.8) <0.0001 - Abstract 273 Table1
% Mortality for Each Group as a Function of CS Dose, mg/g (LD50=2.25)
1.0 1.5 2.0 3.0 4.0 Wt Wt Wt Het Wt+Heme Wt Wt 0.0% (n=17) 8.3% (n=12) 40.9% (n=22) 75.0% (n=12) 6.3% (n=32) 75.0% (n=20) 100.0% (n=6) - Abstract 274 Table1
Fold Change in HO Activity Over Control (VVV). (*p<0.05 vs VHH)
VVV VHH ZL-HH ZBG-HH Liver 1.0±0.2 (n=8) 1.7±0.3 (n=15) 1.5±0.2* (n=11) 1.4±0.3*(n=12) Spleen 1.0±0.3 (n=6) 1.5±0.3 (n=4) 1.4±0.2 (n=4) 1.1±0.2* (n=4) - Abstract 277 Table 1
Hours pH HCO3-(mEq/L) Mean BP
(mmHg)Urine Output
(mL/Kg/h)1–12 7.290±0.081 21.7±1.3 52±3 11.1±5.4 13–24 7.399±0.134 23.9±1.3 47±7 4.4±3.1 25–36 7.267±0.074 22.9±1.4 50±8 4.9±6.0 37–48 7.199±0.129 21.7±3.1 48±8 3.6±3.2 49–60 7.248±0.048 20.0±0.5 34±4 0.9±0.8 61–72 7.018±0.010 18.6±0.1 36±1 0.6±0.1 - Abstract 287 Table 1
Statistically significant outcomes upon ERAS application in 11 studies
Length of Stay Complications Readmits Cost Improved 11 3 1 1 Not Improved/reported 0 8 10 10 Total 11 11 11 11 - Abstract 287 Table 2
Proposed ERAS pathway for plastic surgery
Preoperative Intraoperative Postoperative –Pre–admission patient counseling & education
–Minimize starvation/dehydration
–DVT and antibiotic prophylaxis
–Preoperative warming
–Multimodal prophylactic analgesia–Opioid–sparing anesthetic regimen
–Best surgical techniques
–Euvolemia
–Antiemetics
–Minimize drains
–Intraoperative warming–Postoperative warming
–Early mobilization
–Wound care
–Early resumption of oral hydration and diet
–Multimodal analgesia with opioids for breakthrough pain - Abstract 288 Table 1
Months IEHP Charge Capture All Other Charge Capture P-Values Jan 2013-Jun 2013 11.07% 25.95% 0.001114 Jul 2013-Dec 2013 13.66% 26.65% 0.0003675 Jan 2014-Jun 2014 14.52% 27.77% 7.89E–06 Jul 2014-Dec 2014 15.17% 29.24% 3.69E–05 - Abstract 289 Table 1
Results
Outcomes Correctly Predicted Complications Average Predicted Risk in Study Population (n=104) Actual Incidence in Practice (n=4924) Serious Complication 14 (20.9) 6.3% 67 (1.4) Any Complication 73 (78.5) 8.7% 93 (1.9) Surgical Site Infection 10 (24.4) 3.3% 10 (0.2) Venous Thromboembolism 0 0.4% 1 (0.0) Return to OR 14 (24.1) 4.9% 58 (1.2) - Abstract 290 Table 1
Patient Demographics
Patient Age Cervicomental Classification Scale Score Dose in mL (10 mg / 1 mL) Pain Score Adjunctive Treatments 1 48 2.25 3.4 3 Cheek volume augmentation* 2 39 1.75 3.6 2 Fat grafting** 3 41 2.75 5.6 4 None *Patient 1 underwent treatment with Juvéderm Voluma XC (Allergan, CA USA) in the malar region three weeks prior to injection.
**Patient 2 underwent autologous fat grafting to her mid-face five months prior to injection.
- Abstract 311 Table 1
Breakdown of Colleges
Colleges Attending URM (n=88) Non-URM (n=275) P Value UC 46.00% 45.80% 0.90 Ivy League 1.10% 4.40% 0.56 Top 20 4.60% 6.90% 0.62 Cal State 8.00% 4.00% 0.15 2 Year College 16.00% 1.80% 0.0001 Other 23.90% 37.10% N/A “Top 20” was obtained from USA news' nationwide university ranking.
- Abstract 337 Table 1
Intracellular HO-1-Expression in Blood and Spleen Immune Cells (MFI±SEM)
Blood HO-1 NPR PR LPS-PR p Neutrophils 7048±1614 5276±260# 7777±434# #0.0006 Monocytes 5996±527 5256±243# 10383±602# #< 0.0001 MHC II+ DCs 8999±1329* 5393±281*# 11360±552# *0.0241, #0.0001 Spleen HO-1 Neutrophils 3347±1062 2843±205 3115±138 ns Monocytes 3387±981 2968±211# 0.0±0.0# #< 0.0001 DCs 8089±1100 6488±708 6992±180 ns - Abstract 347 Table 1
Epo (N=24) Placebo (N=26) P value Severe encephalopathy 21% 15% 0.72 In hospital mortality 2 (8%) 5 (19%) 0.47 6 month WIDEA 75.3 (SD 9.0) 69.0 (SD 11.0) 0.04 MRI–normal 8 (36%) 3 (12%) 0.01 MRI–mild injury 13 (59%) 11 (44%) MRI–moderate injury 1 (5%) 6 (24%) MRI–severe injury 0 (0%) 5 (20%) - Abstract 350 Table 1
Maternal and Neonatal Demographics and Outcomes
Insulin N=61 Non-insulin N=69 P- value Birth weight, g* 613±150 786±149 < 0.001 Gestational age, wks.* 25.1±1.6 27±2.7 < 0.001 Chorioamnionitis–N (%) 26 (42.6) 20 (29) 0.11 PIH–N (%) 27 (44.3) 22 (31.9) 0.15 Antenatal Steroids–N. (%) 56 (91.8) 64 (92.8) 0.61 Advanced resuscitation atbirth–N. (%) 29 (47.5) 17 (24.6) 0.005 Vaginal delivery–N (%) 12 (19.7) 7 (10.2) 0.13 Mortality–N (%) 11 (18.3) 5 (7.3) 0.062 Severe IVH–N (%) 6 (9.8) 3 (4.4) 0.21 Severe ROP–N (%) 23 (37.7) 7 (10.2) < 0.001 BPD–N (%) 40 (65.6) 38 (55.1) 0.014 *Mean±SD.
- Abstract 351 Table 1
Risk on TB Nomogram
ETCOc (ppm; median; IQR)ETCOc <1.0 1.0≤ ETCOc ≤1.5 1.5< ETCOc <2.5 ETCOC >2.5 TB<40th %tile (n=18)
ETCOc (1.3; 1.1–1.6)4 (22%) 9 (50%) 5 (28%) 0 (0%) TB=40th to 75th %tile (n=34)
ETCOc (1.2; 1.1–1.7)3 (9%) 19 (56%) 12 (35%) 0 (0%) TB>75 ≤ 95th %tile (n=25)
ETCOc (1.8; 1.4–2.0)0 (0%) 9 (36%) 14 (56%) 2 (8%) TB>95th %tile (n=4)
ETCOc (2.7; 2.4–3.0)0 (0%) 0 (0%) 1 (25%) 3 (75%) Total (n=82) 7 (9%) 38 (47%) 32 (40%) 5 (6%) - Abstract 368 Table 1
Procedure Number Delayed breast reconstruction with tissue expanders, bilateral serratus anterior muscle flap 5 Delayed reconstruction of bilateral breasts with breast implants under TRAM 1 Breast reduction 4 Cheek fasciocutaneous flap for skin cancer reconstruction 2 Finger flexor tendon tenolysis 3 Thumb CMC joint arthroplasty 1 Split thickness skin graft 5 Harvest of skin graft from right leg and skin graft to right and left axillae measuring 430 cm2 1 - Abstract 369 Table 1
Facial Edema and Redness Rating Scale
Pigmentation (Bruising) Redness Turgor (from edema) Swelling (Height) 0, no bruising 0, none 0, normal 0, normal 1, slight bruising 1, light to pink 1, supple 1, <2 mm 2, moderate bruising 2, pink to red 2, yielding 2, 2–5 mm 3, heavy bruising 3, red 3, firm 3, >5 mm 4, vivid red 4, hard - Abstract 371 Table 1
Spider Silk vs. Suture Stress Comparison
Sample Fiber Stress (St. Dev.) Knot Stress (St. Dev.) MaSp1/MaSp2 12 Fiber Thread 147.43 MPa (29.64) 166.93 MPa (12.21) 6–0 Vicryl Suture 368.33 MPa (37.77) 180.88 MPa (11.14)
Vol 64 Issue 1
Table of Contents
- Article
- Joint Plenary Session, WAFMR, WSCI, WAP AND WSPR, 8:00 AM
- Adolescent Medicine and General Pediatrics II, Concurrent Session, 12:30 PM
- Cardiovascular III, Concurrent Session
- Endocrinology and Metabolism II, Concurrent Session
- Gastroenterology, Concurrent Session
- Genetics, Concurrent Session
- Neonatal Pulmonary III, Concurrent Session
- Neonatology General III, Concurrent Session
- Neonatology Perinatal Biology I, Concurrent Session
- Surgery II, Concurrent Session
- Behavior and Development, Concurrent Session, 3:30 PM
- Community Health II, Concurrent Session
- Health Care Research II, Concurrent Session
- Hematology and Oncology II, Concurrent Session
- Infectious Diseases II, Concurrent Session
- Morphogenesis and Malformations, Concurrent Session
- Neonatology General IV, Concurrent Session
- Nephrology and Hypertension, Concurrent Session
- Neuroscience II, Concurrent Session
- Surgery III, Concurrent Session
- Figures & Data
- eLetters
- Info & Metrics